Xavier Montalban, EAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis

Xavier Montalban (St Michael's Hospital, University of Toronto, Toronto, Canada and Vall d'Hebron University Hospital, Barcelona, Spain) shares his expert insights on the potential for Bruton's tyrosine kinase (BTK) inhibitors in the treatment of multiple sclerosis (MS) and other autoimmune diseases, including background and results from the recent phase II study of evobrutinib in relapsing MS.

Questions
1. What is the rationale for the use of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of relapsing multiple sclerosis? (0:04)
2. Could you tell us a little about the recent phase II study of evobrutinib and its safety and efficacy findings? (0:41)
3. What do you consider the major advantages of evobrutinib compared with existing therapies? (1:38)
4. What is the potential for the use of evobrutinib in progressive multiple sclerosis and other autoimmune diseases? (2:19)

Speaker disclosure: Xavier Montalban has received non-financial support from Merck Serono during the conduct of the study discussed for manuscript preparation, as well as personal fees and non-financial support from Biogen, Novartis, Sanofi-Genzyme, Teva Pharmaceuticals, Roche, Celgene, Actelion, Excemed, and Merck Serono.

Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.